The patents for these four compounds are held by the University of North Carolina and UCSF, where Longo worked before coming to Stanford. While at UNC, Longo founded PharmatrophiX, a company focused on the commercial development of small molecules similar to and including those identified in this study.
Related to: The neurotrophic factor BDNF reduces neurodegeneration induced by frataxin deficiency in neuronal cultures.
